Resistant Leishmaniasis Chemotherapy: Scenario of Drug Development

Abstract

The present study highlights the Resistant Leishmaniasis Chemotherapy in Drug Development. Chemotherapy is central to the control and management of leishmaniasis. Antimonials remain the primary drugs against different forms of leishmaniasis in several regions. However, resistance to antimony has necessitated the use of alternative medications, especially in the Indian subcontinent. Antineoplastic agent, miltefosine, introduced as the first efficient treatment orally for VL, which is also an substitute treatment for HIV patients. Greater understanding of resistance mechanisms and use of safe and efficient nano-carriers may be a better strategy to alter the whole scenario of leishmaniasis chemotherapy to benefit patients who are mainly neglected poor people in the future.